RNS System Clinical Trial

RNS System Responsive Stimulation for Teens and Adults with Lennox-Gastaut Syndrome (LGS) Study

The purpose of the RNS System Lennox-Gastaut Syndrome (LGS) study is to generate preliminary safety and effectiveness data for brain-responsive neurostimulation of thalamocortical networks as an adjunctive therapy in reducing the frequency of generalized seizures in individuals 12 years of age or older with LGS who are refractory to antiseizure medications.

The intent is to determine the feasibility and the optimal design of a subsequent pivotal study in order to expand the indication for use for the RNS System as a treatment for patients with medically intractable LGS.

Watch Now: Overview of Responsive Neurostimulation (RNS)

Presented by: Michael Chez, MD, Pediatric Epileptologist, Sutter Health, California

*Dr. Michael Chez is a Pediatric Epilepsy Expert and regularly treats LGS patients. This video was recorded in early 2022 at the request of the LGS Foundation to provide information to our family members about this medication. The Foundation does not endorse this or any product and is here only to provide information relevant to patient families. 


Study Sites:

  • New York University (NY)
  • Massachusetts General Hospital (MA)
  • Mount Sinai (IL)
  • Emory University (GA)
  • University of Alabama at Birmingham (AL)
  • UC San Francisco (CA)

Additional Information:

Visit the RNS Clinical Trial Website

The information here is not intended to provide diagnosis, treatment, or medical advice and should not be considered a substitute for advice from a healthcare professional. The content provided is for informational purposes only. LGS Foundation is not responsible for actions taken based on the information included on this webpage. Please consult with a physician or other healthcare professional regarding any medical or health-related diagnosis or treatment options.

Updated: 7/28/2023